The 37,5000 square foot site was built in response to “increased demand for Phase II and Phase III clinical studies and is a result of continued growth serving new and existing clients” according to Sherpa.
The site will provide primary and secondary clinical labelling and packaging, GMP storage for refrigerated, frozen and controlled room temperature, and temperature controlled shipping dispatch.
It also features an ISO 8 clean room for primary packaging of solid dose products.
The privately owned contractor finished construction of the facility in 2015.
"The new Sherpa facility will help sustain the continued growth of our company," said Mark Paiz, president of Sherpa Clinical Packaging.
"We are excited to be able to provide the diversity and quality of services to a large number of clients in all phases of clinical trials. Sherpa's mission is to be the customer service leader in the clinical trial materials management business and we offer each client the trusting and reliable relationship that people vested in clinical trials seek."